ProPhase Labs Advances Chapter 11 Collections With 50 Insurance Settlements Nearing Completion

Reuters
01/26
<a href="https://laohu8.com/S/PRPH">ProPhase Labs</a> Advances Chapter 11 Collections With 50 Insurance Settlements Nearing Completion

ProPhase Labs Inc. has provided an update on its Crown Medical Collections initiative, which is focused on recovering legacy COVID-19 testing receivables through its laboratory subsidiaries currently in Chapter 11 proceedings. Crown Medical, acting as special counsel, is in settlement negotiations with over 250 insurance payors, with approximately 50 cases in advanced settlement stages and expected to close within the next 30 to 90 days. The anticipated recoveries are projected to significantly improve near-term liquidity, supporting ongoing operations and a court-supervised restructuring process. Net cash recoveries after fees and costs could exceed $50 million, though the final amount remains subject to negotiations and court processes. Remaining proceeds, after satisfying subsidiary creditor obligations, are expected to benefit ProPhase Labs, Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9642105-en) on January 26, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10